Literature DB >> 19766729

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Jason A Coppell1, Paul G Richardson, Robert Soiffer, Paul L Martin, Nancy A Kernan, Allen Chen, Eva Guinan, Georgia Vogelsang, Amrita Krishnan, Sergio Giralt, Carolyn Revta, Nicole A Carreau, Massimo Iacobelli, Enric Carreras, Tapani Ruutu, Tiziano Barbui, Joseph H Antin, Dietger Niederwieser.   

Abstract

The occurrence of hepatic veno-occlusive disease (VOD) has been reported in up to 60% of patients following stem cell transplantation (SCT), with incidence varying widely between studies depending on the type of transplant, conditioning regimen, and criteria used to make the diagnosis. Severe VOD is characterized by high mortality and progression to multiorgan failure (MOF); however, there is no consensus on how to evaluate severity. This review and analysis of published reports attempts to clarify these issues by calculating the overall mean incidence of VOD and mortality from severe VOD, examining the effect of changes in SCT practice on the incidence of VOD over time, and discussing the methods used to evaluate severity. Across 135 studies performed between 1979 and October 2007, the overall mean incidence of VOD was 13.7% (95% confidence interval [CI]=13.3%-14.1%). The mean incidence of VOD was significantly lower between 1979-1994 than between 1994-2007 (11.5% [95% CI, 10.9%-12.1%] vs 14.6% [95% CI, 14.0%-15.2%]; P <.05). The mortality rate from severe VOD was 84.3% (95% CI, 79.6%-88.9%); most of these patients had MOF, which also was the most frequent cause of death. Thus, VOD is less common than early reports suggested, but the current incidence appears to be relatively stable despite recent advances in SCT, including the advent of reduced-intensity conditioning. The evolution of MOF in the setting of VOD after SCT can be considered a reliable indication of severity and a predictor of poor outcome. Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19766729      PMCID: PMC3018714          DOI: 10.1016/j.bbmt.2009.08.024

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  131 in total

1.  Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children.

Authors:  Valérie Lapierre; Cédric Mahé; Anne Aupérin; Férial Stambouli; Nadia Oubouzar; Dominique Tramalloni; Ellen Benhamou; Pierre Tiberghien; Olivier Hartmann
Journal:  Transplantation       Date:  2005-08-15       Impact factor: 4.939

2.  Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.

Authors:  J L Lee; T Gooley; W Bensinger; K Schiffman; G B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

3.  A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.

Authors:  Simone Cesaro; Marta Pillon; Enrico Talenti; Tiziana Toffolutti; Elisabetta Calore; Gloria Tridello; Liliana Strugo; Roberta Destro; Maria Vittoria Gazzola; Stefania Varotto; Gabriella Errigo; Modesto Carli; Luigi Zanesco; Chiara Messina
Journal:  Haematologica       Date:  2005-10       Impact factor: 9.941

4.  Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation.

Authors:  Ioannis Batsis; Evangelia Yannaki; Panayotis Kaloyannidis; Ioanna Sakellari; Christos Smias; Ioannis Georgoulis; Athanasios Fassas; Achilles Anagnostopoulos
Journal:  Thromb Res       Date:  2005-12-05       Impact factor: 3.944

5.  Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.

Authors:  A Clopés; A Sureda; J Sierra; J M Queraltó; A Broto; R Farré; E Moreno; S Brunet; R Martino; M A Mangues
Journal:  Eur J Haematol       Date:  2006-03-27       Impact factor: 2.997

6.  Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.

Authors:  Ursula Haussmann; Joachim Fischer; Stefan Eber; Franziska Scherer; Reinhard Seger; Tayfun Gungor
Journal:  Haematologica       Date:  2006-06       Impact factor: 9.941

7.  Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.

Authors:  P Crilley; D Topolsky; M J Styler; E Bernstein; K Resnick; R Mullaney; S Bulova; I Brodsky; D I Marks
Journal:  Bone Marrow Transplant       Date:  1995-03       Impact factor: 5.483

8.  Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation.

Authors:  A Locasciulli; A Bacigalupo; A Alberti; M T Van Lint; C Uderzo; A M Marmont; H M Shulman; B Portmann
Journal:  Transplantation       Date:  1989-07       Impact factor: 4.939

9.  Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.

Authors:  J Nemunaitis; C S Rosenfeld; R Ash; M H Freedman; H J Deeg; F Appelbaum; J W Singer; N Flomenberg; W Dalton; G J Elfenbein
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Multiple organ dysfunction syndrome in bone marrow transplantation.

Authors:  W D Haire; E I Ruby; B G Gordon; K D Patil; L C Stephens; G D Kotulak; E C Reed; J M Vose; P J Bierman; A Kessinger
Journal:  JAMA       Date:  1995-10-25       Impact factor: 56.272

View more
  131 in total

Review 1.  Hepatic radiation toxicity: avoidance and amelioration.

Authors:  Chandan Guha; Brian D Kavanagh
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

Review 2.  Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.

Authors:  George B McDonald
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

3.  Anicteric veno-occlusive disease after hematopoietic stem cell transplantation in children.

Authors:  J C Naples; M A Skeens; J Auletta; H Rangarajan; R Abu-Arja; E Horwitz; J Stanek; R S Bajwa
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 4.  Acute kidney injury in HCT: an update.

Authors:  J A Lopes; S Jorge; M Neves
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

5.  Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Authors:  Brandon M Triplett; Hani I Kuttab; Guolian Kang; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-14       Impact factor: 5.742

6.  Prophylactic Effect of Recombinant Human Soluble Thrombomodulin for Hepatic Sinusoidal Obstruction Syndrome Model Mice.

Authors:  Shunsuke Kanou; Tomoharu Miyashita; Yasuhiko Yamamoto; Satoshi Takada; Makoto Nakura; Mitsuyoshi Okazaki; Yoshinao Ohbatake; Shinichi Nakanuma; Isamu Makino; Hidehiro Tajima; Hiroyuki Takamura; Sachio Fushida; Tetsuo Ohta
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

7.  Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.

Authors:  Rish K Pai; Koen van Besien; John Hart; Andrew S Artz; Peter H O'Donnell
Journal:  Leuk Lymphoma       Date:  2012-03-13

8.  Role of Initiating Supportive Care Preceding Veno-occlusive Disease Diagnosis Following Allogeneic Hematopoietic Stem Cell Transplantation in Children.

Authors:  Patricia Rayner; Jessica L Spruit; Roland Chu; Maxim Yankelevich; Meret Henry; Yaddanapudi Ravindranath; Süreyya Savaşan
Journal:  J Pediatr Hematol Oncol       Date:  2019-08       Impact factor: 1.289

9.  Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.

Authors:  M Al-Mofareh; M Ayas; A Al-Seraihy; K Siddiqui; A Al-Jefri; I Ghemlas; H Alsaedi; H El-Solh; S Al-Sweedan; B Al-Saud; H Al-Mousa; H Al-Dhekri; R Arnaout; R Mohammed; S Al-Muhsen; A Al-Ahmari
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

10.  Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation.

Authors:  S Weischendorff; K Kielsen; H Sengeløv; K Jordan; C H Nielsen; A E Pedersen; L P Ryder; A Juul; K G Müller
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.